ReviewCurrent opinion in virology2013
T-cell immunity to human alphaherpesviruses.
Review in Current opinion in virology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 80 citations in OpenAlex.
- Th1 memory differentiates recombinant from live herpes zoster vaccines.The Journal of clinical investigation · 2018Trial
- Diversification of the antigen-specific T cell receptor repertoire after varicella zoster vaccination.Science translational medicine · 2016Trial
- A pilot imaging mass cytometry study of cutaneous nerve-immune cell interactions in post-herpetic neuralgia.Frontiers in immunology · 2026Article
- A single-dose mRNA vaccine induces potent and long-lasting humoral and cellular immunity against the varicella-zoster virus in a murine model.Frontiers in immunology · 2026Article
- Live Zoster Vaccination and the Reduced Risk of Chronic Respiratory Diseases: An Emulated Target Trial.Allergy · 2026Article
- Varicella-Zoster Virus Infection and Varicella-Zoster Virus Vaccine-Related Ocular Complications.Vaccines · 2025Review
- Immunogenicity and cellular response of a herpes zoster virus gEgI fusion protein adjuvanted with CpG-emulsion in mice.Journal of nanobiotechnology · 2025Article
- Immune Response Elicited by Recombinant Adenovirus-Delivered Glycoprotein B and Nucleocapsid Protein UL18 and UL25 of HSV-1 in Mice.International journal of molecular sciences · 2024Article
- Expansion of the HSV-2-specific T cell repertoire in skin after immunotherapeutic HSV-2 vaccine.JCI insight · 2024Article
- Preclinical immunogenicity of an adenovirus-vectored vaccine for herpes zoster.Human vaccines & immunotherapeutics · 2023Article
- Pre-Clinical Development of an Adenovirus Vector Based RSV and Shingles Vaccine Candidate.Vaccines · 2023Article
- Varicella-zoster virus proteome-wide T-cell screening demonstrates low prevalence of virus-specific CD8 T-cells in latently infected human trigeminal ganglia.Journal of neuroinflammation · 2023Article
- The impact of HLA polymorphism on herpesvirus infection and disease.Immunogenetics · 2023Review
- Immune changes and their relationship with prognosis in patients with varicella-zoster virus encephalitis/meningitis.American journal of translational research · 2023Article
- Assessing and restoring adaptive immunity to HSV, VZV, and HHV-6 in solid organ and hematopoietic cell transplant recipients.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022Review
- Dynamic Immune Landscape and VZV-Specific T Cell Responses in Patients With Herpes Zoster and Postherpetic Neuralgia.Frontiers in immunology · 2022Article
- Kaposi's sarcoma-associated herpesvirus T cell responses in HIV seronegative individuals from rural Uganda.Nature communications · 2021Article
- Pathogenesis and virulence of herpes simplex virus.Virulence · 2021Review
- Review
- Brain immune cells undergo cGAS/STING-dependent apoptosis during herpes simplex virus type 1 infection to limit type I IFN production.The Journal of clinical investigation · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
Human alphaherpesviruses (αHHV) - herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus (VZV) - infect mucosal epithelial cells, establish a lifelong latent infection of sensory neurons, and reactivate intermittingly to cause recrudescent disease. Although chronic αHHV infections co-exist with brisk T-cell responses, T-cell immune suppression is associated with worsened recurrent infection. Induction of αHHV-specific T-cell immunity is complex and results in poly-specific CD4 and CD8 T-cell responses in peripheral blood. Specific T-cells are localized to ganglia during the chronic phase of HSV infection and to several infected areas during recurrences, and persist long after viral clearance. These recent advances hold promise in the design of new vaccine candidates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.